A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

Joseph Pidala,1,2 Jongphil Kim,2,3 Heather Jim,2,4 Mohamed A. Kharfan-Dabaja,1,2 Taiga Nishihori,1,2 Hugo F. Fernandez,1,2 Marcie Tomblyn,1,2 Lia Perez,1,2 Janelle Perkins,1,2 Mian Xu,1 William E. Janssen,1,2 Anandaraman Veerapathran,1 Brian C. Betts,1,2 Frederick L. Locke,1,2 Ernesto Ayala,1,2 Teresa Field,1,2 Leonel Ochoa,1,2 Melissa Alsina,1,2 and Claudio Anasetti1,2

1Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL; 2Oncologic Sciences, College of Medicine at University of South Florida, Tampa, FL; 3Biostatistics, Moffitt Cancer Center, Tampa, FL; and 4Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA


Online Supplementary Figure S1. Consort flow diagram for trial enrollment, allocation, follow-up and analysis.
Online Supplementary Figure S2. Absolute numbers of Treg at designated time points according to study arm. (MTX = methotrexate/tacrolimus-treated patients, SIR = sirolimus/tacrolimus-treated patients; Treg absolute number units = number of cells/μL). *P* = NS for each comparison.

Online Supplementary Figure S3. Absolute numbers of non-Treg CD4⁺ lymphocytes at designated time points according to study arm. (MTX = methotrexate/tacrolimus-treated patients, SIR = sirolimus/tacrolimus-treated patients; non-Treg CD4⁺ absolute number units = number of cells/μL). *P* = NS for each comparison.